Quantitative liver functions in Turner syndrome with and without hormone replacement therapy

被引:41
作者
Gravholt, Claus Hojbjerg
Poulsen, Henrik Enghusen
Ott, Peter
Christiansen, Jens Sandahl
Vilstrup, Hendrik
机构
[1] Aarhus Univ Hosp, Aarhus Sygehus, Dept Med Endocrinol & Diabet M, DK-8000 Aarhus C, Denmark
[2] Rigshosp, Dept Clin Pharmacol, DK-2100 Copenhagen, Denmark
[3] Aarhus Univ Hosp, Aarhus Sygehus, Dept Hepatogastroenterol, DK-8000 Aarhus C, Denmark
关键词
D O I
10.1530/EJE-07-0070
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Studies have documented elevated levels of liver enzymes in many females with Turner syndrome (TS). Histology has shown a range of changes. Treatment with female hormone replacement therapy (HRT) reduces liver enzymes. Aim: To study quantitative liver functions in TS in detail with and without HRT. Design: Randomized crossover study with active treatment (HRT in TS and P-pill in controls) or no treatment. Subjects: Women with TS (n=8, age 29.7 +/- 5.6 (mean +/- S.D.) years), verified by karyotype, and age-matched controls (C; n=8. age 27.3 +/- 4.9 years). Methods: We determined liver enzymes in blood, used the galactose elimination capacity to assess hepatocyte cytosol activity. plasma clearance of indocyanine green to assess excretory function, antipyrine clearance to estimate microsomal activity, and the functional hepatic nitrogen clearance (FHNC) to assess mitochondrial-cytosolic metabolic capacity for conversion of amino-nitrogen. Results: Liver enzymes were elevated in untreated TS and reduced by HRT. The hepatic capacities for conversion of galactose, indocyanine green, and antipyrine were normal and did not change by HRT. The FHNC was marginally reduced (untreated TS vs C: 19.4 +/- 5.4 vs 25.2 +/- 7.3 L/h, P=0.1). FHNC changed slightly with HRT in TS (19.4 +/- 5.4 vs 24.4 +/- 10.2 L/h, P=0.2). Conclusions: The elevations of liver enzymes in untreated TS are readily suppressed by HRT. Quantitative liver functions in TS are comparable to controls and are not affected by HRT.
引用
收藏
页码:679 / 686
页数:8
相关论文
共 51 条
[1]   Biochemical liver abnormalities in Turner's syndrome [J].
Albareda, MM ;
Gallego, A ;
Enríquez, J ;
Rodríguez, JL ;
Webb, SM .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1999, 11 (09) :1037-1039
[2]   Sex and hepatic fibrosis [J].
Bissell, DM .
HEPATOLOGY, 1999, 29 (03) :988-989
[3]   Progression of liver fibrosis in women infected with hepatitis C: Long-term benefit of estrogen exposure [J].
Di Martino, V ;
Lebray, P ;
Myers, RP ;
Pannier, E ;
Paradis, V ;
Charlotte, F ;
Moussalli, J ;
Thabut, D ;
Buffet, C ;
Poynard, T .
HEPATOLOGY, 2004, 40 (06) :1426-1433
[4]   Hormone replacement therapy may improve hepatic function in women with Turner's syndrome [J].
Elsheikh, M ;
Hodgson, HJF ;
Wass, JAH ;
Conway, GS .
CLINICAL ENDOCRINOLOGY, 2001, 55 (02) :227-231
[5]   The effect of hormone replacement therapy on cardiovascular hemodynamics in women with Turner's syndrome [J].
Elsheikh, M ;
Bird, R ;
Casadei, B ;
Conway, GS ;
Wass, JAH .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (02) :614-618
[6]   A RAPID AND PRECISE METHOD FOR THE DETERMINATION OF UREA [J].
FAWCETT, JK ;
SCOTT, JE .
JOURNAL OF CLINICAL PATHOLOGY, 1960, 13 (02) :156-159
[7]   Vascular endothelial growth factor: Basic science and clinical progress [J].
Ferrara, N .
ENDOCRINE REVIEWS, 2004, 25 (04) :581-611
[8]   Chronic cholestasis associated with Turner's syndrome [J].
Floreani, A ;
Molaro, M ;
Baragiotta, A ;
Naccarato, R .
DIGESTION, 1999, 60 (06) :587-589
[9]  
Garavelli L, 1998, AM J MED GENET, V80, P180, DOI 10.1002/(SICI)1096-8628(19981102)80:2<180::AID-AJMG18>3.0.CO
[10]  
2-U